130A.T
Veritas In Silico Inc.
グロース · 医薬品 · 医薬品 · JP
JPY 434.00
+0.23%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- -91.7%
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +5.8%
Three-year CAGR
- Revenue
- —
- EBITDA
- -93.5%
- EBIT
- -86.8%
- Net income
- -80.1%
- EPS
- -76.8%
- Free cash flow
- -45.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026